Loading clinical trials...
Loading clinical trials...
The primary aim of this validation protocol is to assess cardiovascular function through transthoracic echocardiography ("Echo") measurements and the QuantaFlo HD test measuring blood flow at the finger during a forced expiration ("FE"). The study examines whether Echo-measured GLS values greater than -16% correlate with abnormal responses during FE as measured by QuantaFlo HD.
Age
22 - No limit years
Sex
ALL
Healthy Volunteers
No
Pima Heart and Vascular
Tucson, Arizona, United States
Start Date
August 21, 2025
Primary Completion Date
March 31, 2026
Completion Date
June 30, 2026
Last Updated
October 23, 2025
600
ESTIMATED participants
QuantaFlo HD
DEVICE
Lead Sponsor
Semler Scientific
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions